Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Inovio Pharmaceuticals Inc’s stock clocked out at $2.25, up 1.81% from its previous closing price of $2.21. In other words, the price has increased by $1.81 from its previous closing price. On the day, 0.82 million shares were traded. INO stock price reached its highest trading level at $2.2989 during the session, while it also had its lowest trading level at $2.185.
Ratios:
To gain a deeper understanding of INO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.63 and its Current Ratio is at 2.63. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on May 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $20.
On January 25, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INO now has a Market Capitalization of 82517400 and an Enterprise Value of 25425894. For the stock, the TTM Price-to-Sale (P/S) ratio is 294.70 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 89.813 whereas that against EBITDA is -0.244.
Stock Price History:
The Beta on a monthly basis for INO is 1.33, which has changed by -0.7215346 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, INO has reached a high of $12.33, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is 13.91%, while the 200-Day Moving Average is calculated to be -27.32%.
Shares Statistics:
It appears that INO traded 627.63K shares on average per day over the past three months and 622600 shares per day over the past ten days. A total of 36.67M shares are outstanding, with a floating share count of 36.39M. Insiders hold about 0.79% of the company’s shares, while institutions hold 37.18% stake in the company. Shares short for INO as of 1749772800 were 6460315 with a Short Ratio of 10.29, compared to 1747267200 on 7009769. Therefore, it implies a Short% of Shares Outstanding of 6460315 and a Short% of Float of 17.740000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Inovio Pharmaceuticals Inc (INO).The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.56 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$2.08 and -$2.71 for the fiscal current year, implying an average EPS of -$2.34. EPS for the following year is -$2.11, with 4.0 analysts recommending between -$1.47 and -$2.86.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for INO’s current fiscal year. The highest revenue estimate was $215k, while the lowest revenue estimate was $65k, resulting in an average revenue estimate of $109k. In the same quarter a year ago, actual revenue was $217.76kBased on 5 analysts’ estimates, the company’s revenue will be $16.36M in the next fiscal year. The high estimate is $41.52M and the low estimate is $900k.
